Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | GMNN | O75496 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | BLM | P54132 | 1/20 | 0.36 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4992531 | 1.00 | EPHX1 (0.39) | EPHX1TP53KDM4EGMNNLMNA | |
| SCHEMBL5642596 | 0.98 | EPHX1 (0.36) | EPHX1TP53KDM4EGMNNLMNA | |
| SCHEMBL5195552 | 0.77 | AAK1 (0.31) | EPHX1 | |
| SCHEMBL5195544 | 0.77 | AAK1 (0.31) | EPHX1 | |
| SCHEMBL6356694 | 0.76 | — | — | |
| SCHEMBL5642181 | 0.73 | — | — | |
| SCHEMBL5643344 | 0.69 | — | — | |
| SCHEMBL27306903 | 0.68 | EPHX1 (0.31) | EPHX1 | |
| SCHEMBL5397569 | 0.68 | TP53 (0.37) | EPHX1TP53KDM4EGMNNLMNA | |
| SCHEMBL119958 | 0.68 | EPHX1 (0.35) | EPHX1TP53KDM4EGMNNLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2125021-B8 | COMBINATION THERAPY OF LOWER URINARY TRACT DISORDERS WITH ALPHA 2DELTA LIGANDS AND NSAIDS | RECORDATI IRELAND LTD (IE) | 2012-02-15 | — | — | EP | claimed |
| EP-2125021-B1 | COMBINATION THERAPY OF LOWER URINARY TRACT DISORDERS WITH 2 LIGANDS AND NSAIDS | RECORDATI IRELAND LTD (IE) | 2011-06-08 | — | — | EP | claimed |
| EP-2125021-A1 | COMBINATION THERAPY OF LOWER URINARY TRACT DISORDERS WITH 2 LIGANDS AND NSAIDS | Recordati Ireland Limited (IE) | 2009-12-02 | — | — | EP | claimed |
| WO-2008077599-A1 | COMBINATION THERAPY OF LOWER URINARY TRACT DISORDERS WITH α2δ LIGANDS AND NSAIDS | RECORDATI IRELAND LIMITED (IE) | 2008-07-03 | — | — | WO | claimed |
| US-20080153888-A1 | ALPHA-2-DELTA LIGAND/NSAID THERAPEUTIC TREATMENT OF LOWER URINARY TRACT DISORDERS | RECORDATI IRELAND LIMITED (IE) | 2008-06-26 | — | — | US | claimed |
| US-7250433-B2 | Tetrazole and oxadiazolone substituted β-amino acid derivatives | WARNER LAMBERT COMPANY LLC (US) | 2007-07-31 | — | — | US | claimed |
| EP-1603890-A1 | TETRAZOLE AND OXADIAZOLONE SUBSTITUTED &bgr;-AMINO ACID DERIVATIVES | Warner-Lambert Company LLC (US) | 2005-12-14 | — | — | EP | claimed |
| US-20050014804-A1 | Tetrazole and oxadiazolone substituted beta-amino acid derivatives | BARTA NANCY SUE (US) | 2005-01-20 | — | — | US | claimed |
| WO-2004078734-A1 | TETRAZOLE AND OXADIAZOLONE SUBSTITUTED β-AMINO ACID DERIVATIVES | WARNER-LAMBERT COMPANY LLC (US) | 2004-09-16 | — | — | WO | claimed |
| EP-2125021-B8 | COMBINATION THERAPY OF LOWER URINARY TRACT DISORDERS WITH ALPHA 2DELTA LIGANDS AND NSAIDS | RECORDATI IRELAND LTD (IE) | 2012-02-15 | — | — | EP | disclosed |
| EP-2125021-B1 | COMBINATION THERAPY OF LOWER URINARY TRACT DISORDERS WITH 2 LIGANDS AND NSAIDS | RECORDATI IRELAND LTD (IE) | 2011-06-08 | — | — | EP | disclosed |
| EP-2125021-A1 | COMBINATION THERAPY OF LOWER URINARY TRACT DISORDERS WITH 2 LIGANDS AND NSAIDS | Recordati Ireland Limited (IE) | 2009-12-02 | — | — | EP | disclosed |
| WO-2008077599-A1 | COMBINATION THERAPY OF LOWER URINARY TRACT DISORDERS WITH α2δ LIGANDS AND NSAIDS | RECORDATI IRELAND LIMITED (IE) | 2008-07-03 | — | — | WO | disclosed |
| US-20080153888-A1 | ALPHA-2-DELTA LIGAND/NSAID THERAPEUTIC TREATMENT OF LOWER URINARY TRACT DISORDERS | RECORDATI IRELAND LIMITED (IE) | 2008-06-26 | — | — | US | disclosed |
| US-7250433-B2 | Tetrazole and oxadiazolone substituted β-amino acid derivatives | WARNER LAMBERT COMPANY LLC (US) | 2007-07-31 | — | — | US | disclosed |
| US-7250433-B2 | Tetrazole and oxadiazolone substituted β-amino acid derivatives | WARNER LAMBERT COMPANY LLC (US) | 2007-07-31 | — | — | US | disclosed |
| EP-1603890-A1 | TETRAZOLE AND OXADIAZOLONE SUBSTITUTED &bgr;-AMINO ACID DERIVATIVES | Warner-Lambert Company LLC (US) | 2005-12-14 | — | — | EP | disclosed |
| US-20050014804-A1 | Tetrazole and oxadiazolone substituted beta-amino acid derivatives | BARTA NANCY SUE (US) | 2005-01-20 | — | — | US | disclosed |
| WO-2004078734-A1 | TETRAZOLE AND OXADIAZOLONE SUBSTITUTED β-AMINO ACID DERIVATIVES | WARNER-LAMBERT COMPANY LLC (US) | 2004-09-16 | — | — | WO | disclosed |
| WO-2004078734-A1 | TETRAZOLE AND OXADIAZOLONE SUBSTITUTED β-AMINO ACID DERIVATIVES | WARNER-LAMBERT COMPANY LLC (US) | 2004-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014804-A1 | Tetrazole and oxadiazolone substituted beta-amino acid derivatives | GLRA2, CACNG5, GLRB | EPHX1 2214/4885TP53 4457/4885KDM4E 2993/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.